Animal Stem Cell Therapy Sales

Animal Stem Cell Therapy Sales Market Outlook

The global animal stem cell therapy market is projected to reach approximately USD 1.5 billion by 2035, growing at a robust CAGR of around 17% from 2025 to 2035. This impressive growth is driven by increasing investments in advanced veterinary medicine, rising awareness of stem cell therapy benefits, and the growing incidence of chronic diseases in animals. Furthermore, the expansion of veterinary healthcare facilities and advancements in regenerative medicine techniques are contributing significantly to the market's growth. The emphasis on improving animal health and welfare is also leading to enhanced adoption of innovative treatment options such as stem cell therapy, which is poised to revolutionize the veterinary landscape. Additionally, partnerships and collaborations among veterinary professionals and research institutions are accelerating the development of effective therapies, further expanding market opportunities.

Growth Factor of the Market

The animal stem cell therapy market is experiencing significant growth due to various factors influencing its advancement. One of the primary growth drivers is the increasing prevalence of age-related diseases and conditions in companion animals, which necessitates innovative treatment options. Moreover, advancements in stem cell research and technology have led to more effective and safer therapies, enhancing the acceptance of these treatment modalities among veterinarians and pet owners. The rising trend of pet humanization has also sparked greater demand for high-quality, specialized healthcare services, including stem cell therapies. Furthermore, increased funding and investments in veterinary research and development are facilitating the discovery of new applications for stem cell therapy in various animal species. Lastly, the growing collaboration between commercial entities and research institutions is paving the way for novel treatment approaches that are expected to propel market growth in the coming years.

Key Highlights of the Market

• The global animal stem cell therapy market is projected to expand at a CAGR of 17% from 2025 to 2035.
• Increasing incidence of chronic diseases in animals is a significant market driver.
• The rise of veterinary hospitals and advanced healthcare facilities is enhancing market accessibility.
• There is growing public awareness regarding the benefits of stem cell therapy for pets.
• Technological advancements in regenerative medicine are improving therapy outcomes.

By Product Type

Autologous Stem Cells:

Autologous stem cells are derived from the same individual animal, making them a favored choice for many veterinarians. The primary advantage of using autologous stem cells is the reduced risk of immune rejection, as the cells are derived from the patient's own body. This type of stem cell therapy is commonly employed in treating various conditions, including orthopedic disorders and soft tissue injuries. The market for autologous stem cells is witnessing significant growth, as advancements in collection and processing techniques are making this therapy more effective and accessible for veterinary practitioners. The rising trend of pet humanization and the increasing expenditures on companion animal healthcare further fuel the demand for autologous therapies. As more pet owners become aware of the benefits associated with this type of stem cell treatment, the segment is poised for continued growth over the next decade.

Allogeneic Stem Cells:

Allogeneic stem cells are sourced from a donor animal and can be used to treat multiple patients, making them a cost-effective option in many cases. This type of therapy is gaining traction due to its ability to provide immediate treatment options for animals that may not have sufficient time for autologous cell preparation. Allogeneic stem cells are commonly used in treating various conditions, including oncological and orthopedic disorders. The segment is growing as veterinary practices increasingly adopt allogeneic therapies to expand their treatment offerings. Additionally, the potential for improved outcomes compared to traditional treatment methods is driving interest in this segment. As the regulatory landscape surrounding stem cell therapy continues to evolve, the allogeneic stem cell market is expected to flourish, providing valuable treatment options for both companion and livestock animals.

Xenogeneic Stem Cells:

Xenogeneic stem cells, which are harvested from a different species, are being explored for their potential therapeutic applications in veterinary medicine. While this segment is not as prevalent as autologous or allogeneic therapies, it is gaining attention for specific cases where other options may be limited. Research into xenogeneic stem cells is ongoing, with studies focusing on their efficacy and safety in treating a variety of conditions. The market for these stem cells is primarily driven by advancements in biotechnology and a growing interest in exploring alternative sources for stem cell therapy. As research continues to validate the applications of xenogeneic stem cells, it is likely that this segment will witness enhanced growth, especially in specialized veterinary practices aimed at addressing complex medical conditions in animals.

iPSCs:

Induced pluripotent stem cells (iPSCs) represent a revolutionary approach in stem cell therapy, offering the unique ability to differentiate into any cell type. This versatility makes iPSCs particularly promising for regenerative medicine applications in veterinary contexts. The adoption of iPSCs in animal stem cell therapy is still in its nascent stages; however, ongoing research is uncovering their potential in treating various disorders, including genetic and degenerative diseases. The ability to generate patient-specific cell lines from iPSCs opens up new avenues for personalized treatment approaches and enhanced therapeutic efficacy. As scientific understanding of iPSCs continues to grow, the market for these advanced stem cells is anticipated to expand significantly over the coming years, driven by increasing investment in veterinary regenerative medicine and favorable regulatory developments.

By Application

Veterinary Hospitals:

Veterinary hospitals are pivotal in the delivery of animal stem cell therapies, as they have the infrastructure and expertise required for advanced treatment modalities. The rising number of specialized veterinary hospitals and clinics is contributing to the increased adoption of stem cell therapy. These facilities typically offer a comprehensive range of services, including diagnostics, treatment, and rehabilitation, creating a favorable environment for the implementation of innovative therapies. The growing public concern over animal health and welfare has led pet owners to seek out advanced treatment options, further driving the demand for stem cell therapy in veterinary hospitals. Additionally, collaborations between veterinary hospitals and research institutions are fostering the development of new therapeutic protocols, ensuring that pet owners receive the most effective care possible.

Research Institutes:

Research institutes play a crucial role in advancing animal stem cell therapy by conducting studies that lead to the discovery of new applications and treatment methodologies. These institutes are at the forefront of exploring the potential of stem cells in various veterinary applications, from regenerative medicine to disease modeling. The data generated from research initiatives informs best practices and contributes to the growing body of knowledge surrounding stem cell therapy. As more research institutes focus on animal health, there is a greater likelihood of breakthroughs that will enhance therapeutic options available in the market. The collaboration between research institutes and commercial entities is also critical for translating laboratory findings into practical therapies, ensuring that animals benefit from scientific advancements in stem cell technology.

Veterinary Clinics:

Veterinary clinics serve as the primary point of contact for pet owners seeking healthcare solutions for their animals. As awareness of stem cell therapy increases, many clinics are beginning to incorporate these services into their offerings. The accessibility of stem cell therapies in veterinary clinics is becoming a significant driver of market growth, as pet owners appreciate the convenience of receiving advanced treatments in familiar settings. Clinics that adopt these innovative therapies can differentiate themselves in a competitive market by providing cutting-edge solutions to common ailments faced by companion animals. Additionally, the training and education of veterinary staff on the benefits and procedures related to stem cell therapy are essential for increasing adoption rates and ensuring positive outcomes for animal patients.

Others:

This segment includes various applications of animal stem cell therapy that do not fit neatly into the previously discussed categories. These may involve specialized treatment centers, mobile veterinary services, or research-based applications focused on species not typically seen in conventional veterinary practices. The diversity of applications under this category reflects the expanding scope of veterinary medicine and the increasing interest in integrating cutting-edge therapies into a wider array of animal healthcare settings. As awareness of the benefits of stem cell therapy grows, more innovative applications are likely to emerge, further contributing to the overall market expansion and providing pet owners with a broader range of healthcare options for their animals.

By End User

Companion Animals:

The companion animals segment is the most significant contributor to the animal stem cell therapy market due to the deep emotional bond between pets and their owners. As more pet owners seek effective treatments for chronic conditions, the demand for stem cell therapies is expected to rise. Common conditions treated through stem cell therapy in companion animals include orthopedic issues, degenerative diseases, and wound healing. The trend of pet humanization is notably influencing this segment, as owners increasingly prioritize high-quality healthcare for their pets. As veterinary practices continue to integrate advanced treatment options, the companion animal segment is likely to witness sustained growth, fueled by increased spending on pet healthcare and the growing acceptance of innovative therapies.

Livestock Animals:

While the companion animal segment dominates the market, the livestock animal sector is also emerging as a crucial area for the application of stem cell therapy. The adoption of stem cell therapies in livestock is driven by the need for improved animal health and productivity, as well as the desire to mitigate losses associated with disease outbreaks. Stem cell therapy has the potential to enhance growth rates, reproductive performance, and overall herd health, making it an attractive option for livestock producers. As awareness of the benefits of stem cell therapy grows within the agricultural community, the market for livestock applications is expected to expand significantly. Furthermore, with the increasing focus on sustainable farming practices, regenerative therapies like stem cell treatment are likely to play a vital role in the future of animal agriculture.

Others:

This segment encompasses various end users, including exotic and wild animals, as well as research applications. The growing interest in the conservation of endangered species and wildlife rehabilitation is driving the exploration of stem cell therapy in these areas. As veterinary medicine evolves to address the needs of diverse animal populations, the market is expected to see increased application of stem cell therapies in non-traditional settings. Moreover, collaborative efforts among veterinary researchers, conservationists, and wildlife rehabilitators are paving the way for innovative treatments that can benefit both domestic and wild animal species. As awareness of the potential of stem cell therapy in various contexts grows, this segment is likely to contribute to the overall market growth, further expanding the scope of animal stem cell therapy.

By Therapy Type

Oncological Disorders:

Oncological disorders in animals represent a significant challenge for veterinary practitioners, necessitating the development of effective treatment options. Stem cell therapy is being explored as a promising approach for addressing various types of cancers in animals, including lymphomas and solid tumors. Research has shown that stem cells can potentially aid in tumor regression and improve the quality of life for affected animals. The segment is gaining traction due to advancements in understanding cancer biology and the therapeutic potential of stem cell-based treatments. As more veterinary practices adopt these innovative therapies and clinical trials demonstrate their efficacy, the market for oncological applications of stem cell therapy is expected to grow significantly over the forecast period.

Orthopedic Disorders:

Orthopedic disorders are among the most common ailments affecting both companion and livestock animals, making this therapy type a crucial segment of the animal stem cell therapy market. Stem cell therapy offers regenerative potential that can significantly improve the healing of bone and cartilage injuries, promoting faster recovery and restoring mobility. This segment has gained widespread acceptance among veterinary practitioners, with many clinics incorporating stem cell treatments as a standard part of their orthopedic care protocols. The increasing incidence of joint-related issues, especially in aging animals, further propels the demand for effective therapies. As research continues to validate the benefits of stem cell therapy for orthopedic disorders, this segment is likely to witness robust growth, supported by increased investment in veterinary orthopedic care.

Wound Healing:

Wound healing is a critical area where stem cell therapy is being utilized to enhance recovery outcomes in animals. Stem cells can facilitate tissue regeneration and repair by promoting the formation of new blood vessels and enhancing healing processes. The application of stem cell therapy for wound healing is gaining traction in both companion and livestock animals, particularly for chronic wounds and surgical sites that exhibit delayed healing. The rising prevalence of traumatic injuries and the need for effective wound management solutions are driving interest in this segment. As veterinarians continue to embrace advanced therapeutic modalities, the market for stem cell therapy focused on wound healing is poised for significant growth, driven by positive clinical outcomes and increasing awareness among pet owners regarding innovative treatment options.

Others:

This segment includes various other therapy types that may not fit neatly into the previously mentioned categories. These could involve applications for metabolic disorders, neurological conditions, or degenerative diseases that require tailored therapeutic approaches. The emergence of personalized medicine in veterinary care is driving interest in exploring diverse therapeutic applications of stem cell treatment, leading to new discoveries. As research continues to expand the understanding of stem cell applications in various medical contexts, this segment is likely to see growth, bolstered by the increasing demand for specialized care for complex medical conditions in animals.

By Region

The animal stem cell therapy market exhibits regional variations, with North America leading the charge due to its advanced veterinary infrastructure and high adoption rates of innovative treatment modalities. The market in North America is expected to grow significantly, with a projected CAGR of around 18% during the forecast period. Factors such as increased pet ownership, a growing focus on animal health, and the presence of leading veterinary research institutions contribute to the robust growth of the region. Veterinary hospitals and clinics in North America are increasingly adopting stem cell therapies, resulting in a growing consumer base that seeks advanced treatment options for their pets.

In Europe, the animal stem cell therapy market is also on an upward trajectory, driven by rising awareness and acceptance of innovative therapies among pet owners and veterinarians alike. The European market is characterized by stringent regulations and comprehensive veterinary care systems, which support the development and adoption of new treatment modalities. The growing emphasis on animal welfare, coupled with increasing investments in veterinary research, is propelling the market in this region. Meanwhile, the Asia Pacific region is emerging as a significant player in the animal stem cell therapy market, driven by increasing pet ownership rates, disposable income, and the growing acceptance of advanced veterinary treatments. The concerted efforts to enhance animal healthcare infrastructure and regulatory frameworks further position the Asia Pacific region for substantial growth in the coming years.

Opportunities

The animal stem cell therapy market is poised for significant opportunities driven by various factors. As the awareness of regenerative medicine grows, both pet owners and animal health professionals are increasingly seeking advanced therapeutic options that stem cell therapy can provide. One of the key opportunities lies in expanding the scope of applications for stem cell therapy beyond traditional use cases. For instance, there is a growing interest in utilizing stem cells for treating metabolic and genetic disorders in animals, which presents an avenue for developing new therapies and protocols. Additionally, the potential for iPSCs and other novel stem cell types opens new research opportunities, enabling the exploration of personalized medicine approaches tailored to individual patients. As research institutions and veterinary practices collaborate more closely, the development of customized therapies for specific animal breeds and conditions could further enhance the overall market landscape.

Moreover, the adoption of advanced technologies in the veterinary field, such as telemedicine and digital health solutions, creates opportunities for integrating stem cell therapies into comprehensive treatment plans. The increasing availability of telehealth services can facilitate education and awareness regarding stem cell therapy, allowing pet owners to make informed decisions about their pet's healthcare. Furthermore, as the regulatory environment continues to evolve, there is potential for increased acceptance and support for stem cell-based treatments in veterinary medicine. This could lead to a reduction in barriers to entry for new therapies and encourage more companies to invest in the development of innovative stem cell applications. Overall, the combination of technological advancements, regulatory support, and an increasing focus on animal health and welfare presents a wealth of opportunities for growth in the animal stem cell therapy market.

Threats

Despite the promising growth trajectory of the animal stem cell therapy market, several threats could pose challenges to its expansion. One significant threat is the regulatory hurdles associated with stem cell therapies, which can create delays in product development and market entry. Varying regulations across different countries regarding the use of stem cells in veterinary medicine may hinder the adoption of innovative therapies, especially for international companies looking to expand their reach. Additionally, there is a growing concern regarding the ethical implications of using stem cells, particularly with respect to sourcing and the potential for fraud or misinformation in the veterinary market. Increased scrutiny from regulatory agencies and advocacy groups may lead to stricter regulations, posing challenges for companies operating in this space.

Moreover, the perception of stem cell therapy as being experimental or unproven may deter some pet owners from seeking these treatment options for their animals. Misconceptions surrounding the safety and efficacy of stem cell therapy could lead to reluctance in adoption, particularly among conservative pet owners. Additionally, competition from alternative treatment modalities, such as traditional veterinary medicine and other regenerative therapies, may limit the market share of stem cell therapies. Companies must continuously invest in research and education to effectively communicate the benefits and safety of these treatments to both veterinarians and pet owners. Addressing public concerns and misconceptions will be crucial in mitigating these threats and ensuring the sustainable growth of the animal stem cell therapy market.

Competitor Outlook

• VetStem Biopharma
• Regeneus
• Mesoblast
• Animal Stem Cells
• VetiVax
• Stem Cell Technologies
• Zymergen
• Aratana Therapeutics
• Pet Stem Cells
• VetCell Therapeutics
• Celerion
• Regenexx
• Avant Genetics
• Boehringer Ingelheim
• Eligo Bioscience

The competitive landscape of the animal stem cell therapy market is characterized by a diverse array of companies specializing in various aspects of stem cell research, development, and commercialization. The market is dominated by a few key players with established reputations and broad portfolios of advanced therapies. These companies often collaborate with academic institutions to drive innovation and bring cutting-edge products to market. Additionally, emerging players are entering the market with unique approaches to stem cell therapy and specialized applications, contributing to a dynamic competitive environment. The ongoing research and development efforts in regenerative medicine are fostering a culture of competition that encourages companies to differentiate their offerings and enhance therapeutic efficacy to meet the evolving needs of the veterinary community.

VetStem Biopharma is one of the leading companies in the animal stem cell therapy market, recognized for its development of autologous stem cell therapies for treating orthopedic and soft tissue injuries in companion animals. The company has established a strong brand presence and a loyal customer base through successful clinical outcomes and extensive partnerships with veterinary clinics. Regeneus is another prominent player focusing on developing innovative stem cell therapies for both companion and livestock animals, with a focus on regenerative medicine applications aimed at improving animal health and welfare. Their collaborations with research institutions ensure that they remain at the forefront of scientific advancements in the field.

Companies like Mesoblast and Animal Stem Cells are similarly engaged in advancing animal stem cell therapy, leveraging their research capabilities to create effective therapies for a range of conditions. These organizations are investing significantly in clinical trials to validate their products and demonstrate their effectiveness, thus fostering trust and acceptance among veterinary professionals and pet owners. Additionally, notable companies such as VetCell Therapeutics and Aratana Therapeutics are carving niches in the market with their specialized treatment offerings, reinforcing the competitive landscape of this rapidly evolving industry.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 VetiVax
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Celerion
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Regeneus
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Regenexx
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Zymergen
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Mesoblast
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Avant Genetics
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Pet Stem Cells
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Eligo Bioscience
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Animal Stem Cells
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 VetStem Biopharma
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Aratana Therapeutics
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Boehringer Ingelheim
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 VetCell Therapeutics
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Stem Cell Technologies
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Animal Stem Cell Therapy Sales Market, By End User
    • 6.1.1 Companion Animals
    • 6.1.2 Livestock Animals
    • 6.1.3 Others
  • 6.2 Animal Stem Cell Therapy Sales Market, By Application
    • 6.2.1 Veterinary Hospitals
    • 6.2.2 Research Institutes
    • 6.2.3 Veterinary Clinics
    • 6.2.4 Others
  • 6.3 Animal Stem Cell Therapy Sales Market, By Product Type
    • 6.3.1 Autologous Stem Cells
    • 6.3.2 Allogeneic Stem Cells
    • 6.3.3 Xenogeneic Stem Cells
    • 6.3.4 iPSCs
  • 6.4 Animal Stem Cell Therapy Sales Market, By Therapy Type
    • 6.4.1 Oncological Disorders
    • 6.4.2 Orthopedic Disorders
    • 6.4.3 Wound Healing
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Animal Stem Cell Therapy Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Animal Stem Cell Therapy Sales market is categorized based on

By Product Type

• Autologous Stem Cells
• Allogeneic Stem Cells
• Xenogeneic Stem Cells
• iPSCs

By Application

• Veterinary Hospitals
• Research Institutes
• Veterinary Clinics
• Others

By End User

• Companion Animals
• Livestock Animals
• Others

By Therapy Type

• Oncological Disorders
• Orthopedic Disorders
• Wound Healing
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• VetStem Biopharma
• Regeneus
• Mesoblast
• Animal Stem Cells
• VetiVax
• Stem Cell Technologies
• Zymergen
• Aratana Therapeutics
• Pet Stem Cells
• VetCell Therapeutics
• Celerion
• Regenexx
• Avant Genetics
• Boehringer Ingelheim
• Eligo Bioscience